Time filter

Source Type

PubMed | Minia University, Ain Shams University, Menoufia University, Egyptian Company for Blood Transfusion Services Egyblood VACSERA; Agouza and University of Maryland Baltimore County
Type: Journal Article | Journal: PloS one | Year: 2014

Hepatitis C Virus (HCV) infection is a global health burden particularly in Egypt, where HCV genotype 4a (GT-4a) predominates. The prevention and control of HCV infection will remain a challenge until the development of an effective vaccine that protects against different genotypes. Several HCV GT-1-based vaccines are in different stages of clinical trials, but antigenic differences could make protection against other genotypes problematic. In this regard, data comparing the cell-mediated immune (CMI) response to different HCV genotypes are limited. We aimed to ex vivo investigate whether GT-1-based vaccine may protect against HCV GT-4 infections. This was carried out on samples collected from genotype 4 infected/exposed subjects.The CMI responses of 35 subjects; infected with HCV GT-4/or who had spontaneously-resolved the infection and 10 healthy control subjects; to two sets of seven HCV overlapping 15-mer peptide pools derived from both genotypes; and covering most of the viral proteins; were evaluated. This was carried out using an interferon gamma (IFN) enzyme-linked immunospot (ELISpot) assay. Peripheral blood mononuclear cells (PBMC) from 17 subjects (48%) responded to at least one peptide pool derived from GT-1b/GT-4a with 13 subjects responding to peptide pools from both genotypes. A strong correlation was found in the responses to both genotypes (r=0.82, p<0.001; 95% confidence interval=0.562-0.933). The average IFN total spot forming cells (SFC)/10(6) PBMC (SE) from the responding subjects for GT-1b and GT-4a was 21656 and 19955, respectively (p=0.833). Also, there were no significant differences between those who cleared their HCV infection or who remained HCV-RNA positive (p=0.8).Our data suggest that an effective GT-1b vaccine could protect from GT-4a infection. These data could help in HCV rationale vaccine design and efficacy studies and further our understanding of HCV cross protection against different genotypes.

Loading Egyptian Company for Blood Transfusion Services Egyblood VACSERA; Agouza collaborators
Loading Egyptian Company for Blood Transfusion Services Egyblood VACSERA; Agouza collaborators